STAT3 and obesity disorder: Similarly, in a study evaluating the anti-diabetic and anti-obesity impact of the inhibitor 4-(biphenyl-4-ylmethylsulfanylmethyl)-N-(hexane-1-sulfonyl) benzoylamide (KY-226), it was found that oral administration of KY-226 decreased weight gain, food consumption, and fat volume gain, in addition to finding increases in phosphorylated STAT3 in the hypothalamus [114].